I. MODIFIED AGREEMENTS
 
Biotech Co.*
(Country; Symbol)
Pharma Co. (Country) Change from original agreement Terms/Details (Date)

FEBRUARY 2009
 
Ablynx NV (Belgium; BR:ABLX) Novartis AG (Switzerland) Extended for another year a drug discovery and development alliance for nanobody-based therapeutics against disease targets that are difficult  to address with conventional antibodies or their fragments As part of the collaboration, Ablynx receives license fees and funding for research and development; Ablynx is eligible for milestone payments and royalties upon commercialization (2/5)
 
BioFocus DPI (UK; division of Galapagos; BR:GLPG) Eli Lilly and Co. Extended drug discovery agreement until the end of the year BioFocus will identify active compounds by screening Lilly's library compounds; the agreement, started in March 2005, is focused on discovering new compounds that target specific cellular signal  transduction pathways (2/24)
 
Palatin Technologies Inc. (AMEX:PTN) AstraZeneca plc (UK) Extended exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors and a  clinical trial sponsored research agreement Palatin received $4.1M as part of the extension (2/12)
 
XOMA Ltd. (XOMA) Takeda Pharmaceutical Co. Ltd. (Japan) Expanded collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and  development technologies and integrated information and data management systems XOMA will receive a $29M expansion fee and may receive potential milestones and royalties on antibody products; XOMA also may incur $7.5M in taxes and other costs related to the expansion (2/10)
 
MARCH 2009
 
Angiotech Pharmaceuticals Inc. (Canada; ANPI) Baxter International Inc. Restructured partnership for Coseal surgical sealant Angiotech opted to receive $25M in lieu of future milestone and royalty revenues from Baxter, and Baxter gained expanded world-wide rights to the product (3/31)
 
Dynavax Technologies Corp. (DVAX) AstraZeneca plc (UK) Extended research collaboration until 2010 to develop drugs for asthma and chronic obstructive pulmonary disease based on Dynavax's immunostimulatory sequences The firms have moved AZD1419, the first candidate, toward the clinic and may start Phase I testing in the second half of this year (3/11)
 
EffRx Inc.* Nycomed A/S (Denmark) Licensing agreement that will expand the territories for EffRx's EX101 for the treatment of osteoporosis The deal now covers the whole world, except the U.S., Japan, South African countries and a few other minor markets; EffRx will receive up to $15M in additional up-front and milestone payments (3/30)
 
Tekmira Pharmaceuticals Corp. (Canada; TSX:TKM) Bristol-Myers Squibb Co. Exercised option to extend through this year the research collaboration between the two companies The collaboration focuses on validating gene targets using small interfering RNA provided by BMS and employing Tekmira's stable nucleic-acid lipid particle formulations to deliver the siRNA (3/25)
 
Vyteris Inc.

(OTC BB:VYTR)

Ferring Pharmaceuticals Inc. (Switzerland) Agreement to provide additional funding for the first half of the 2009 development budget for a pulsatile delivery of a peptide hormone for  treatment of infertility in women Ferring has committed to pay the first half of the budgeted costs of up to $3.3M, with cash proceeds committed to the infertility project, and Vyteris to fund the second half of the 2009 development budget (3/25)
 
APRIL 2009
 
Nuevolution A/S* (Denmark) Merck & Co. Inc. Agreement to proceed to the second phase of a June 2008 collaboration agreement to apply Nuevolution's Chemetics drug discovery technology to identify novel small-molecule leads against several drug targets Merck thus gains access to a new multi- million member library of small-molecule leads against several drug targets (4/2)
 
II. TERMINATED AGREEMENTS
 
BioAlliance Pharma SA (France; Paris:BIO) SpePharm Holdings BV (the Netherlands) Terminated licensing agreement for the distribution of Loramyc, a muco-adhesive buccal tablet for treating oropharyngeal candidiasis Details were not disclosed (2/27)
 
GTC Biotherapeutics Inc. (GTCB) LEO Pharma AS (Denmark) Terminated a 2005 contract for commercialization and development of ATryn in Europe, Canada and the Middle East GTC is seeking damages from LEO under International Chamber of Commerce arbitration procedures (3/16)
 
Micromet Inc. (MITI) MedImmune Inc. (unit of Astra-Zeneca plc; UK) Terminated agreement that returns rights in North America to the BiTE antibody candidate, blinatumomab, also known as MT103, to Micromet Micromet is conducting a Phase II trial to treat acute lymphoblastic leukemia and a Phase I trial to treat non-Hodgkin's lymphoma (3/12)

Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

BR = Brussels Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.